Iron-overload-induced ferroptosis in mouse cerebral toxoplasmosis promotes brain injury and could be inhibited by

Chong Wang1,2, Linding Xie1,2, Yien Xing1,2

  • 1Department of Health Inspection and Quarantine, School of Public Health, Anhui Medical University, Hefei, China.

PubMed

Insights

Iron dysregulation in cerebral toxoplasmosis (CT) activates ferroptosis. The iron chelator Deferiprone (DFP) reversed this, reducing parasite burden and brain damage in mice.

Area of Science:

  • Neuroparasitology
  • Iron Metabolism
  • Cellular Death Pathways

Background:

  • Cerebral toxoplasmosis (CT) pathogenesis involving iron is poorly understood.
  • Iron is essential for parasite survival and host cell function.
  • Deferiprone (DFP) is an iron chelator that promotes iron excretion.

Purpose of the Study:

  • To investigate iron alterations in the brain during acute Toxoplasma gondii (T. gondii) infection.
  • To explore the role of ferroptosis in CT.
  • To evaluate DFP's therapeutic potential for CT.

Main Methods:

  • Established a mouse model of cerebral toxoplasmosis using TgCtwh3 strain.
  • Treated mice and HT-22 cells with DFP.
  • Assessed T. gondii burden, ferroptosis markers, inflammatory factors, and brain pathology.
  • Utilized qRT-PCR, ICP-MS, Western blot, and microscopy.

Main Results:

  • T. gondii infection activated ferroptosis pathways and caused hippocampal damage.
  • DFP treatment conferred ferroptosis resistance, reduced inflammation and parasite load, and improved survival.
  • DFP inhibited the ferroptosis pathway in infected HT-22 cells in vitro.
  • DFP mitigated mitochondrial damage and inflammation in infected cells.

Conclusions:

  • T. gondii manipulates host iron metabolism, inducing ferroptosis in CT.
  • DFP demonstrates therapeutic potential by counteracting ferroptosis and reducing pathology.
  • This study elucidates CT mechanisms and supports DFP as a treatment option.